



CASE 4-20890C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1632

CUENOUD ET AL.

APPLICATION NO: 10/696,488

FILED: OCTOBER 29, 2003

FOR: 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE
DERIVATIVES

Mail Stop: Missing Parts
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE MISSING PARTS

Sir:


The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed on October 27, 2004 (a copy of which is enclosed), has a shortened statutory time set to expire on December 27, 2004.


In response, Applicants now submit a nucleotide and/or amino acid sequence submission, including a computer readable copy, a paper copy and a Statement Verifying Submission of the Sequence Listing.

Applicants believe that no fee is required with this filing. However, if a fee is deemed to be due, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
617/871-3343
Date: December 22, 2004


Paul Paglierani
Attorney for Applicants
Reg. No. 52,498



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NUMBER | FILING OR 371 (c) DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|------------------------|-----------------------|------------------------|
| 10/696,488 | 10/29/2003 | Bernard Cuenoud | 4-20890C |

001095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 430/2
EAST HANOVER, NJ 07936-1080

RSB
WRD
LTTT

CONFIRMATION NO. 7737

FORMALITIES LETTER



OC000000014212274

Date Mailed: 10/27/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>
- For Patent Software Program Help, call (571) 272-2510 or email mark.spencer@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450



A copy of this notice MUST be returned with the reply.

SEQUENCE LISTING REQUIREMENTS

DOCKETED FOR: Dec. 27, 2004

Guidi N.
Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY